Replies to post #226174 on Biotech Values

[DewDiligence]

EARS lunges at—but misses—the COVID-19 bandwagon:

https://www.globenewswire.com/news-release/2020/09/08/2090096/0/en/Auris-Medical-Launches-Development-of-Drug-Free-Nasal-Spray-for-Protection-against-Airborne-Pathogens-and-Allergens.html

• Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021

• Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%

• Creation of dedicated subsidiary, Altamira Medica Ltd, to focus solely on AM-301 development program

• CHF 1.5 m convertible loan arranged in support of development program

The stock is down 7%.